“…Kaplan–Meier and Cox proportional hazards regression analysis were used to compare their overall survival (OS) and disease-free survival (DFS) of 5 years. RESULTS: We included 4,086 patients (1,117, 1,019, 869, and 1,081 in the T1, T2a, T2b, and T3 groups, respectively). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We included phase II and III randomized controlled trials that looked at the efficacy of PD-1/PD-L1 inhibitors in the treatment of TNBC and reported either Overall Survival (OS), Progression-Free Survival (PFS), or pathological Complete Response (pCR). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Patients in the TP combined with ICIs group had higher overall survival (OS) and progression-free survival (PFS) than those in the PF combined with ICIs group [hazard ratio (HR) = 1.702, 95% confidence interval (CI): 0.767–1.499, p = 0.0167 and HR = 1.158, 95% CI: 0.828–1.619, p = 0.0055] ORR and DCR were 15.7% (13/83) and 85.5% (71/83) in the TP chemotherapy alone group, significantly higher than the PF group [13.6% (12/88) and 72.2% (64/88)] (p < 0.05), OS and PFS were also better in patients treated with TP regimen chemotherapy than PF (HR = 1.173, 95% CI: 0.748–1.839, p = 0.0014 and HR = 0.1.245, 95% CI: 0.711–2.183, p = 0.0061). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, a significant association was observed between a low baseline percentage of CD4(+)CD26(high) T cells (< 7.3%) and clinical outcomes, measured as overall survival (p = 0.010) and progression-free survival (p = 0.014). Moreover, patients with clinical benefit from nivolumab therapy had significantly higher frequencies of circulating CD4(+)CD26(high) T cells than patients with non-clinical benefit (p = 0.004) at 12 months. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…After median follow up of 37 months, median progression-free survival (PFS) of the entire cohort was 10.3 [95% confidence interval (CI): 8.64–11.50] months and median overall survival (OS) was 20 (95% CI: 15.61–23.13) months. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…For secondary outcomes, SpiroDex patients had a significantly greater number of oxygen free days and reached oxygen freedom sooner than the Dex group. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The primary endpoint was progression-free survival (PFS). Tumor evaluations were performed every 2 months using Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In BiVP, pre-stretch occurs only in a single LV free wall (LVfw) segment, but all septal segments display a distinct oscillatory pattern. …”
Enlace del recurso
Enlace del recurso

“…Prior pacing (RV apex, RV and LV free wall, also biventricular) was present in 27 patients. …”
Enlace del recurso
Enlace del recurso

“…During follow up, mean PVCs burden was 7,3±9%, with a mean and median burden reduction (Δ) of 69±41% and 96%. The rate of event-free survival was 69%. Multisite RF and coronary venous system RF were predictors of recurrence (HR 3,81; 95% CI 1,14–12,66; p=0,02 and HR 3,88; 95% CI 1,23 – 12,27; p=0,01), while procedural success was protective (HR 0.1; CI 0.03 - 0.33, p < 0.001). …”
Enlace del recurso
Enlace del recurso

“…However, non-pulmonary vein triggers, emerging from e.g. the superior vena cava, left atrial posterior free wall, left atrial appendage (LAA), terminal crest and interatrial septum, play also an important role in a significant part of AF patients. …”
Enlace del recurso
Enlace del recurso

“…After 12-month 80% of patients in the Heliostar™ and 79% of patients in the CB group (p=0.9) were free from atrial arrhythmias. CONCLUSION: The novel multi-electrode RF-balloon has shown to be safe and effective with good long-term results. …”
Enlace del recurso
Enlace del recurso

“…During a mean follow-up of 204±82 days, 54/67 (81%) in the X-ray group vs. 27/34 (79%) in the 3D group remained free of any symptomatic or documented AF/AFL/AT episode after a single procedure (p=ns). …”
Enlace del recurso
Enlace del recurso

“…During a mean FU of 346±64 days, 88 of 107 patients (82%) remained free of any symptomatic or documented AF/AFL/AT episode after a single procedure. …”
Enlace del recurso
Enlace del recurso

“…With the optimised protocol of delivering the S2 at 400 ms using a 20 ms decrement definition, the sensitivity remains high at 76.9% with an improved specificity of 79.0%, thus reducing the ablation target area by 50% to 16.8 cm2. 92% patients were free of any VT after DeEP-400 guided ablation at 6-month median follow-up. …”
Enlace del recurso
Enlace del recurso

“…At the time of this analysis, the first hundred patients in each group reached one-year follow-up. Recurrence free survival after one year for patients with PAF was 82,6% in CB and 80,0% in PFA. …”
Enlace del recurso
Enlace del recurso

“…Reach is our primary implementation outcome, while “facility-free days” is our primary effectiveness outcome across evidence-based practice interventions. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Before evaluating the bacterial strains for plant growth potential, a control experiment was also conducted to determine the highest critical Zn level from ZnO to wheat growth using different Zn levels (0.1, 0.05, 0.01, 0.005, and 0.001% Zn) against two wheat varieties (Wadaan-17 and Zincol-16) in sand culture under glasshouse conditions. Zinc-free Hoagland nutrients solution was used to irrigate the wheat plants. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…High TSC22D3 expression was significantly associated with poor overall survival (OS) and event-free survival (EFS) in adult AML patients. Univariate and multivariate Cox analysis showed that overexpression of TSC22D3 was independently associated with adverse OS of adult AML patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso